Clinical/Translational Cancer Immunotherapy
Section edited by Dr. James L. Gulley
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
- RESEARCH ARTICLE
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...Journal for ImmunoTherapy of Cancer 2017 5:76Published on: 17 October 2017 - RESEARCH ARTICLE
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...Journal for ImmunoTherapy of Cancer 2017 5:74Published on: 19 September 2017 - RESEARCH ARTICLE
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...Journal for ImmunoTherapy of Cancer 2017 5:72Published on: 19 September 2017 - RESEARCH ARTICLE
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...Journal for ImmunoTherapy of Cancer 2017 5:70Published on: 19 September 2017 - RESEARCH ARTICLE
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...Journal for ImmunoTherapy of Cancer 2017 5:73Published on: 19 September 2017 - RESEARCH ARTICLE
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...Journal for ImmunoTherapy of Cancer 2017 5:71Published on: 19 September 2017 - RESEARCH ARTICLE
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...Journal for ImmunoTherapy of Cancer 2017 5:52Published on: 20 June 2017 - RESEARCH ARTICLE
Evaluation of dosing strategy for pembrolizumab for oncology indications
Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...Journal for ImmunoTherapy of Cancer 2017 5:43Published on: 16 May 2017 - RESEARCH ARTICLE
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...Journal for ImmunoTherapy of Cancer 2017 5:35Published on: 18 April 2017 - RESEARCH ARTICLE
Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors
Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (T...Journal for ImmunoTherapy of Cancer 2017 5:37Published on: 18 April 2017 - MEETING REPORT
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting
As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...Journal for ImmunoTherapy of Cancer 2017 5:38Published on: 18 April 2017 - RESEARCH ARTICLE
Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death
We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...Journal for ImmunoTherapy of Cancer 2017 5:32Published on: 18 April 2017 - RESEARCH ARTICLE
A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood
Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...Journal for ImmunoTherapy of Cancer 2017 5:30Published on: 18 April 2017 - RESEARCH ARTICLE
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...Journal for ImmunoTherapy of Cancer 2017 5:39Published on: 18 April 2017 - RESEARCH ARTICLE
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...Journal for ImmunoTherapy of Cancer 2017 5:22Published on: 21 March 2017 - RESEARCH ARTICLE
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...Journal for ImmunoTherapy of Cancer 2017 5:26Published on: 21 March 2017 - SHORT REPORT
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...Journal for ImmunoTherapy of Cancer 2017 5:23Published on: 21 March 2017 - RESEARCH ARTICLE
CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo
Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...Journal for ImmunoTherapy of Cancer 2017 5:14Published on: 21 February 2017 - RESEARCH ARTICLE
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...Journal for ImmunoTherapy of Cancer 2017 5:4Published on: 17 January 2017 - CASE REPORT
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...Journal for ImmunoTherapy of Cancer 2017 5:1Published on: 17 January 2017
.png)
No hay comentarios:
Publicar un comentario